Advanced in Empty Sella Syndrome

Aneal A. Khan

Calgary, AB, CA 
Advanced in Empty Sella Syndrome
Calgary, AB, CA 
OverviewLocationsClinical Research

Overview

Aneal Khan practices in Calgary, Canada. Khan is rated as an Advanced expert by MediFind in the treatment of Empty Sella Syndrome. Their top areas of expertise are Fabry Disease, Urea Cycle Disorders (UCD), Kearns-Sayre Syndrome, Tissue Biopsy, and Splenectomy.

Their clinical research consists of co-authoring 85 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Empty Sella Syndrome.

Locations

Calgary, AB, Canada
Other Locations
SK, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

The Guard1 Trial, an Open-Label, Multinational Phase 1/2 Study of the Safety and Efficacy of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-02 for Subjects With Type 1 Gaucher Disease
The Guard1 Trial, an Open-Label, Multinational Phase 1/2 Study of the Safety and Efficacy of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-02 for Subjects With Type 1 Gaucher Disease
Enrollment Status: Terminated
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: AVR-RD-02
Study Phase: Phase 1/Phase 2
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
An Open-Label, Multinational Study Of The Efficacy And Safety of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease
An Open-Label, Multinational Study Of The Efficacy And Safety of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Drug
Study Drug: AVR-RD-01
Study Phase: Phase 1/Phase 2
A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease
A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Biological
Study Phase: Phase 3
View 3 Less Clinical Trials

84 Total Publications

Reduced-intensity conditioning in LV-mediated gene therapy for Fabry disease targeting HSPCs.
Reduced-intensity conditioning in LV-mediated gene therapy for Fabry disease targeting HSPCs.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Khan's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 36 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile